Title: A systematic review of the use of quality of life instruments in randomised controlled trials of psoriasis

FM Ali¹, AC Cueva¹, ², J Vyas¹, AA Atwan¹, MS Salek³, ⁴, AY Finlay¹*, V Piguet¹*

¹Department of Dermatology and Academic Wound Healing, Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
²Centro de la Piel, Quito, Ecuador
³School of Life and Medical Sciences, University of Hertfordshire, Hatfield, UK
⁴Institute for Medicines Development, Cardiff, UK.

Running head: Systematic review on the use of QoL Instruments in RCTs of psoriasis

*Correspondence:
- Prof V. Piguet, Department of Dermatology, Division of Infection and Immunity, School of Medicine, Cardiff University, 3rd Floor Glamorgan House, Heath Park, Cardiff CF14 4XN, UK
  email: piguetv@cardiff.ac.uk, tel: 02920 744721
- Prof A.Y. Finlay, Department of Dermatology, Division of Infection and Immunity, School of Medicine, Cardiff University, 3rd Floor Glamorgan House, Heath Park, Cardiff CF14 4XN, UK
  email: FinlayAY@cardiff.ac.uk

Funding: none

Conflicts of Interest

AYF is joint copyright owner of the DLQI and Cardiff University receives some income from the use of the DLQI. AYF has had paid consultancies or advisory boards with Novartis, Napp Pharmaceuticals, Pfizer, Sanofi, and Galderma. VP has received educational and/or research grants from Abbvie, Cellgene, Novartis, J&J.
SS has received educational and/or research grants from Sanofi, Novartis, BMS, Pfizer & Sevier.
FA, AC, JV, AA declare no conflicts of interest.

What's already known about this topic?
- Psoriasis significantly impacts quality of life (QoL) in patients.
- Generic, skin-specific and disease-specific instruments are used in psoriasis interventional studies.
- In psoriasis randomized controlled trials (RCTs), biologics are the most researched interventions that report QoL.

What does this study add?
- The most commonly used QoL instruments in psoriasis RCTs are the DLQI, SF-36 & EQ-5D.
- There is an increasing use of QoL instruments in RCTs in psoriasis.
- Minimal clinically important difference of QoL measure scores is under-reported
- There is inconsistent reporting of QoL data and a need for guidelines when reporting.

Keywords: Psoriasis, systematic review, quality of life, treatment, DLQI

Manuscript word count: 2445 (excluding abstract)
Manuscript table count: 1
Manuscript figure count: 4

ORCID Numbers:

Faraz Ali: 0000-0002-4184-2023
Andrea Cueva: 000-0002-6260-370X
Jui Vyas: 0000-0003-2839-2651
Sam Salek: 0000-0002-4612-5699
Andrew Finlay: 0000-0003-2143-1646
Vincent Piguet: 0000-0001-6079-4517
Abstract

Background
Planners of interventional studies in psoriasis face the dilemma of selecting suitable quality of life (QoL) measures. Systematic reviews (SR) have the potential of identifying psychometrically sound measures in a given therapeutic area, whilst guiding the development of practice guidelines.

Objectives
The aim of this SR was to generate evidence of the use of QoL instruments in randomised controlled trials (RCTs) for interventions in psoriasis.

Methods
The methodology followed PRISMA guidelines. Six databases were searched with 388 search terms. Abstracts of articles were reviewed independently by two assessors, a third adjudicator resolved any opinion differences. Risk of bias was assessed using the JADAD scale.

Results
Of 3646 screened publications, 99 articles (100 trials) met eligibility criteria for inclusion, describing research on 33,215 subjects. 33 trials tested topical therapy, 18 systemic, 39 biologics, 9 phototherapy and 10 tested other interventions. The Dermatology Life Quality Index (DLQI) was the most commonly used QoL instrument (number of studies=83, 83%), followed by the Short Form-36 (SF-36) (31, 31%), EuroQoL (EQ-5D) (15, 15%), Psoriasis Disability Index (PDI) (14,14%) and Skindex (5, 5%). There was widespread inconsistency in the way that QoL data was reported. Of the 100 trials identified, 37 reported Minimal Clinically Important Difference (MCID); 32 were for DLQI, 10 for SF-36 and six for EQ-5D.

Conclusions
QoL measurement is increasingly being reported in RCTs of psoriasis. Formal guidelines are needed for assessment and publishing of QoL data. Researchers should consider whether MCID information is available, and development of MCID data should be encouraged.
Introduction

From the psoriasis patient’s perspective, quality of life (QoL) improvement is as important as improvement in clinical signs. Health-related QoL (HRQoL) instruments are increasingly used as outcome measures in assessing interventions. Types of HRQoL instruments used include generic, speciality-specific and disease-specific; specific tools are perceived as more relevant and thus preferred by patients.

Previous reviews have examined the impact of psoriasis interventions on QoL. De Korte et al. reviewed QoL data with clinical and demographic correlations. Kitchen et al. carried out a systematic review (SR) of patient-reported outcome measures and evidence of their validation in psoriasis. These reviews underscored the value of QoL measurement in psoriasis. However, we need to understand how QoL has been reported in previous trials; a comprehensive review is needed of the use of QoL instruments in randomized controlled trials (RCTs) for interventions in psoriasis.

The aims of this SR were to identify RCTs of therapies in psoriasis that have assessed QoL and to evaluate patterns of utility and reporting of QoL data. This SR should reveal how QoL instruments have been used across therapeutic trials, including consideration of the minimal clinically important difference (MCID), frequency of measurement and sensitivity to change. The review may be useful for those who wish to understand the patterns of use in interventional trials for psoriasis.

Materials and Methods

Data sources

We searched six computerized bibliographical databases up to November 2014: Cochrane Library CENTRAL, MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, WEB OF SCIENCE Core Collection, SCOPUS. The search was restricted to publications in English and was conducted using PRISMA guidelines (Prospero registration no: CRD42015009193).

Keywords were formulated using Scottish Intercollegiate Guidelines Network (SIGN) and COCHRANE search filters for RCTs and SCHARR search filters for QoL. Keywords for psoriasis treatments were developed through a pilot search of other SRs on psoriasis treatments and of the British National Formulary. Search filters are given in the Supplementary Material. We ran supplementary searches and reviewed trial registers and grey literature. Reference lists of all included studies and of recent reviews were also assessed. Electronic publications in advance of print were also included.

Selection criteria

We included RCTs of any psoriasis treatment using at least one QoL instrument in adults (aged 18 and over) with psoriasis of either sex and of any ethnicity, including all psoriasis subtypes of psoriasis. Psoriatic arthritis trials were only included if a
skin-specific QoL instrument was used to differentiate QoL impairment for arthritis from that of psoriasis.

Exclusion criteria

The exclusion criteria for the systematic review were as follows; psoriatic arthritis studies where it was not possible to differentiate data on QoL impact of arthritis from QoL impact of psoriasis, studies which included any patient less than 18 years of age, and articles where the change in QoL values cannot be reliably calculated (including graphical representation). For consistency, QoL data only presented as sub-scales, where total scores are usually calculated, were excluded. Abstracts and posters where further data is not available upon contacting the author were also excluded.

Outcome measures extracted

Primary Outcome

Data recorded included QoL instrument used and scores at baseline, treatment and follow-up endpoints and change in QoL attributed to treatment. For studies with an open label extension, the data was only extracted for the period of the study while it was randomised and controlled. For cross-over trials, the data was extracted prior to the crossover.

Secondary Outcomes

Psoriasis Area and Severity Index (PASI) score or any other psoriasis severity scale (PSS) used.

Data extraction and synthesis

Two reviewers (FA and AC) extracted data independently from all eligible published studies, discussed any disagreements and, if necessary involved a third reviewer (AA) for resolution. We adapted a form, which included the Cochrane Risk of Bias tool, for recording data that included study design, details of administration, methodological quality and duration of treatment and follow-up. Article quality was quantitatively rated using the JADAD score.

We recorded PASI or any other PSS and all QoL data including the baseline, treatment and follow-up endpoint scores and whether the studies detailed QoL percentage change, full scores, graphs or MCID.

Results

Of 3646 screened records, 99 articles met the inclusion criteria, describing 100 RCTs and 33,215 patients (Fig. 1). Some trials were reported in more than one publication: all relevant references are given in Table 1. Sixty-three studies were placebo-controlled, 33 head-to-head trials and 36 tested a single drug in different dosage regimens or formulations (total >99 as studies fulfilled more than one criterion). Although JADAD scores were not integral to the inclusion criteria, Table 1 ranks interventions from low to high methodological quality.
Of the 100 trials that measured QoL, 33 tested topical, 18 systemic, 39 biologics, 9 phototherapy, and 10 tested other interventions including educational treatments, diet, writing exercises, balneotherapy, auriculotherapy, relaxation therapies and interdisciplinary care (Table 1, Fig. 2 and Fig. 5). The number of studies reporting each topical intervention were: calcipotriol (13 trials), calcipotriol/bethametasone (7), clobetasol (4) and dithranol (4). Systemic medications trials included: methotrexate (7), ciclosporin (3) and voclosporin (2). Biologic trials included etanercept (14), ustekinumab (8), adalimumab (7), infliximab (6) and alefacept (4). Quality of life was evaluated in nine phototherapy trials. In the category of “other interventions” QoL was used most commonly in educational (3) and diet (3) studies.

The mean JADAD score was 3.34 (range 1-5, Table 1). QoL was tested a range of 2-6 times for topical, 2-25 times for systemic and 2-12 times for biologic interventions. Sixteen trials lasted >12 weeks, 49 from 12 to 24 weeks and 35 >24 weeks. The subject number ranged from 20 to 2546 patients, with a mean male: female ratio of 1.7:1 per study arm. Mean PASI at baseline ranged from 1.7 to 33.1.

The range of mean QoL scores at baseline were: Dermatology Life Quality Index (DLQI) 1.7-20.1 (Minimum-maximum for this measure = 0-30); Short Form 36 (SF-36) physical component summary (PCS) 32.7-56.2 (0-100) and mental component summary (MCS) 35.7-52.4 (0-100); EuroQoL (EQ-5D) Component I 0.48-0.74 (0 to 1), EuroQoL Component II 55.3-76.4 (0-100); and Psoriasis Disability Index (PDI) 7.6-52.6 (0-90).

Instruments used

Thirteen instruments were used to measure QoL; some studies used more than one. Five generic instruments were used: the SF-36; EQ-5D; General Health Questionnaire (GHQ-12); Quality of Life Index (QLI); and Sickness Impact Profile (SIP). In addition, four dermatology specific instruments, three specific to psoriasis and one for scalp dermatitis were used: DLQI; Skindex; Dermatology Quality of Life Scales (DQOLS); Freiburg Life Quality Assessment (FLQA-d); PDI; 12-Item Psoriasis Quality of Life Questionnaire (PQOL); Psoriatic Arthritis Quality of Life measure (PsAQoL); and SCALPDEX. Of these, the DLQI was the most commonly used QoL instrument (number of studies=83, 83%), followed by the SF-36 (31, 31%), EQ-5D (15, 15%), PDI (14, 14%) and Skindex (5, 5%).

Minimal Clinically Important Difference (MCID) and Statistical Reporting

Of the 100 trials identified, 37 reported MCID; 32 were for DLQI, 10 for SF-36 and six for EQ-5D. The DLQI MCID was considered to be a score change of five but is now reported as four. Of the 83 RCTs that utilised the DLQI, 32 trials reported the MCID. Change in mean DLQI scores from baseline to treatment end ranged from -14.4 to +3.0. Where DLQI score changes were reported, 115 of 142 ‘study arms’ met the 4-point MCID. Biologic interventions usually attained DLQI MCID: 91.2% (83 of 91 study arms) met the 4-point MCID. The MCID was attained by 77.8% (14 of 18) of topical, and 52.4% (11 of 21) of systemic treatment arms. One RCT of infliximab measuring QoL at 100 weeks reported 3 points worsening of DLQI. However, this study ended prematurely and had a low JADAD score of only 2.
Another trial, with a high JADAD score of 5 \(^{36}\) demonstrated mean DLQI score increasing by 0.4 after folic acid was added to methotrexate. The MCID was not met for any study arm.

The SF-36 MCID is a change of three in the total score \(^{37}\). The SF-36 was used in 31 trials and MCID reported in 10. The mean SF-36 change from baseline to treatment end ranged from PCS -7.4 \(^{35}\) to +10.1 \(^{38,39}\) MCS from -0.3 \(^{40}\) to +12.2 \(^{39}\). Where extracting change in SF-36 MCS scores was possible, 52.2% (24 of 46) ‘study arms’ met the 3-point MCID: 58.3% (21 of 36) of biologic interventions met this. For PCS scores, 50% (24 of 48) of ‘study arms’ met the MCID as did 60.5% (23 of 38) of biologic interventions. Only 25% (1 of 4) of systemic and no topical treatments met the MCID for both MCS and PCS domains.

The EQ-5D was used in 15 trials, 6 reported the MCID which is 0.05 \(^{41,42}\). The PDI was used in 14 trials: the MCID is not known. Skindex was used in five RCTs; MCIDs for Skindex versions have not been published.

Fig. 3 shows correlation between PASI and absolute DLQI \((R^2=0.494)\) and percentage \((R^2=0.641)\) score changes, where available. In some cases the correlation was weak \(^{43}\), possibly attributed to non-optimal endpoint measurement for QoL where maximum effect may be missed \(^{44}\). Furthermore some interventions may have a psychological impact not captured by clinical parameters.

Table 1 gives the studies included that documented full QoL data and statistical significance for intervention versus comparator. Significant changes were reached in 52 trials for the DLQI, 19 for the SF-36, 5 for both the EQ-5D and PDI and 2 for the Skindex. Conversely there was no statistical improvement in 19 trials for the DLQI, 6 for the SF-36, 3 for the EQ-5D, 6 for the PDI and 3 for Skindex. Twelve trials did not report statistical significance for the DLQI, 6 for the SF-36, 4 for the EQ-5D and 2 for the PDI.

The first two studies identified, that fulfilled inclusion criteria, were published in 1998 \(^{45,46}\). Since then, reports of psoriasis interventions that fulfilled inclusion criteria have gradually increased over time: 1998-2004 = 12, 2005-2009 = 33, and 2010-2014 = 55 (Fig. 4).

**Discussion**

QoL assessment is a frequent component in assessing psoriasis treatment efficacy \(^{47}\). This SR has identified therapeutic RCTs that demonstrated extractable QoL data, inevitably with heterogeneity in design, disease severity and QoL reporting. Many trials were excluded because of inconsistent reporting and analysis of QoL (Fig. 1) \(^{48}\). Baseline and end-of-treatment values were not always provided. Often QoL scores were presented as percentage or value changes without pre or post-intervention scores. Mean values were most commonly reported, though median values are preferable with ordinal data \(^{47}\). Standard deviation, \(p\)-values or confidence intervals were sometimes omitted and intention-to-treat (ITT) numbers were sometimes omitted from the QoL data set. This presented challenges for synthesizing data.

The MCID is the minimal change in score that is considered of clinical relevance \(^{49}\).
Of the 13 QoL instruments used, only the DLQI, SF-36 and EQ-5D have MCID values reported in the literature. Although interventions may result in statistically significant QoL improvement, this does not necessarily correlate with clinically important change. MCID values enhance the clinical meaningfulness of QoL scores, particularly if data is correlated with clinical efficacy. Thirty-seven trials reported consideration of MCID, with the DLQI and SF-36 being the most commonly used instruments with known MCID. The EQ-5D was the only other used instrument with known MCID; this data is not reported as numbers were so low.

The MCID of QoL measures may be determined using several methodologies, and at least nine approaches have been reported. These may be categorised into two main groups: anchor-based and distribution based approaches. Whereas the former incorporates patient perspective, the latter determines MCID using statistical significance. The anchor-based method is the most commonly used for determining the MCID, as used in the case of the DLQI.

Each methodology has its limitations, for example, anchor-based methods have often been criticised for unequal changes required for deterioration versus improvement of a condition. Several factors may influence MCID scores, including patient baseline status, disease group and severity, treatment and patient demographics. Furthermore, it is important to note that MCID values may differ significantly within the same population depending on the methodology chosen. Therefore interpreting MCID scores should be considered in the context of these limitations.

More generic QoL instruments were used (n=5) than specialty (n=4) or condition specific questionnaires (n=3). The DLQI was the most commonly used instrument; possibly because of the simplicity of reporting a single summary score, the ease of completion in 2 minutes, its widespread use in national psoriasis guidelines amongst other reasons. The frequency of QoL measurement varied across studies depending on intervention type and trial duration. The UK guidelines, that recommend DLQI measurement at 10 to 16 weeks depending on the biologic, may not capture the best DLQI responses for biologic therapies.

Several reviews have explored the effects of biologic treatment on QoL, Other SRs have explored QoL in psoriasis; the review by De Korte et al. was not limited to RCTs and this provided difficulties in interpreting the dataset. This SR investigates the patterns of use of QoL instruments as well as the reporting of the outcomes. We employed strict entry criteria allowing for robust comparison across interventions per QoL instrument. We only included data from the double-blind controlled phases of each trial. Nevertheless, the lack of adequate guidelines on QoL data reporting still rendered data analysis problematic.

Kitchen et al. reviewed the ability of psoriasis-specific instruments to adequately capture domains relating to psoriasis: no existing psoriasis specific patient reported outcome (PRO) instrument has sufficient evidence on validity, reliability and sensitivity to change, but both DLQI and Skindex demonstrated content validity. However, this SR demonstrates that several generic and disease/specialty-specific instruments were sensitive to change with positive QoL outcomes.

The DLQI and SF-36 are the most frequently used instruments across psoriasis RCTs. A European S3 guidelines report on psoriasis systemic treatment described
the DLQI as an ‘important’ variable in assessment of treatment efficacy. However the DLQI has limitations, including previous criticisms of its uni-dimensionality and low representation of emotional aspects. There is diverse practice in monitoring therapeutic effect on QoL and questionnaire preference. We rejected 113 RCTs because of inextricable QoL data. The European Academy of Dermatology and Venereology Task Force provides recommendations for use of QoL measures. Currently there is great variation in the quality of reporting of QoL data, creating difficulties in cross-interventional meta-analyses. This SR emphasizes the need for guidelines concerning appropriate reporting of QoL data.

This review has several limitations. Only English language literature was examined and only studies with extractable QoL data were included. There was too little comparative data from other QoL instruments to be included. Several studies were excluded due to inadequate QoL data reporting. Collating data across studies other than RCTs was not possible due to the wide variation in methodologies. Although an author (AYF) is joint DLQI copyright holder, bias was countered by two independent principal reviewers conducting data search, extraction and synthesis, with a third independent adjudicator reviewer.

We recommend improvement of QoL reporting to include baseline, treatment and follow-up endpoint absolute median scores with interquartile range. Patient numbers should always be reported as well as whether intention to treat was implemented, as previously suggested. If a graphical representation of QoL is published, it should be accompanied by numerical data. Authors should not submit only percentage and/or graphical data to represent study outcomes as this data cannot be used in meta-analysis and systematic reviews. Journals should furthermore implement such criteria prior to accepting publications. The MCID and validated band descriptors where available should be used to interpret data as this holds greater clinical value than statistical significance alone. Researchers should consider the availability of MCID when choosing QoL instruments, and be encouraged to publish MCID information. Whilst there are numerous approaches for calculating MCID scores, there is a need for consensus on new or improved methodological approaches towards calculating MCID. Existing methodologies should be cautiously taken into account by clinicians and researchers alike to facilitate the interpretation of results. Though minimal change is clinically important, the question arises of whether intervention endpoints should target perfect quality of life, rather than demonstrating a measurable improvement.

Acknowledgments

We would like to thank Matthew Manfre and Clarissa Rizzo from Malta University Medical School, who aided with preliminary research for this study. We would also like to thank Dr. John Ingram (Cardiff University) for his invaluable support and guidance throughout the study. Finally we acknowledge the National Institution of Higher Education, Science, Technology and Innovation-SENESCYT, who made it possible for Dr Andrea Cueva to contribute to this review.
REFERENCES
4 Menter A, Abramovits W, Colón LE et al. Comparing clobetasol propionate 0.05% spray to calcipotriene 0.005% betamethasone dipropionate 0.064% ointment for the treatment of moderate to severe plaque psoriasis. *J. Drugs Dermatol.* 2009; **8**: 52-7.
17 Gelfand JM, Kimball AB, Mostow EN et al. Patient - Reported Outcomes and Health - Care Resource Utilization in Patients with Psoriasis Treated with


32 Khilji FA, Gonzalez M, Finlay AY. Clinical meaning of change in Dermatology Life Quality Index scores. *British journal of dermatology-supplement* 2002; 147: 50-.

33 Basra MKA, Salek MS, Camilleri L *et al.* Determining the minimal clinically important difference and responsiveness of the Dermatology Life Quality Index (DLQI): further data. *Dermatology* 2015; 230: 27-33.


67 Shikiar R, Heffernan M, Langley RG et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis:
Patient-reported outcomes from a Phase II randomized controlled trial. *Journal of Dermatological Treatment* 2007; **18**: 25-31.


73 Revicki D, Menter A, Feldman S *et al.* Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. *Health and quality of life outcomes* 2008; **6**: 75.


80 Lui H, Gulliver W, Tan J *et al.* A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for


95 Dauden E, Griffiths CEM, Ortonne JP et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving


140  McInnes IB, Kavanaugh A, Gottlieb AB et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the


154 Asawanonda P, Nateetongrungsak Y. Methotrexate plus narrowband UVB phototherapy versus narrowband UVB phototherapy alone in the treatment of


159 Koek MBG, Buskens E, Van Weelden H *et al.* Home versus outpatient ultraviolet B phototherapy for mild to severe psoriasis: Pragmatic multicentre randomised controlled non-inferiority trial (PLUTO study). *Bmj* 2009; **338**: 1181-6.

160 Koek MBG, Buskens E, Steegmans PHA *et al.* UVB phototherapy in an outpatient setting or at home: A pragmatic randomised single-blind trial designed to settle the discussion. The PLUTO study. *BMC Med Res Methodol* 2006; **6**.


174 Bergstrom KG, Arambula K, Kimball AB. Medication Formulation Affects Quality of Life: A Randomized Single-Blind Study of Clobetasol Propionate Foam 0.05% Compared With a Combined Program of Clobetasol Cream 0.05% and Solution 0.05% for the Treatment of Psoriasis. *Cutis* 2003; **72**: 407-11.


176 Sofen H, Hudson CP, Cook-Bolden FE et al. Clobetasol propionate 0.05% spray for the management of moderate-to-severe plaque psoriasis of the scalp: results from a randomized controlled trial. *J. Drugs Dermatol.* 2011; **10**: 885-92.


180 Tiplica G, Salavastru C. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. *J. Eur. Acad. Dermatol. Venereol.* 2009; **23**: 905-12.


Table 1. Included studies: Jadad score, treatment duration, sample characteristics, QoL instruments and main psoriasis severity scale used

<table>
<thead>
<tr>
<th>Main QoL article, Year (salami publications used to derive non-QoL data)</th>
<th>JADAD</th>
<th>Interventions (Grouped per intervention, ranked by increasing JADAD score)</th>
<th>Treatment End point (Weeks) Unless specified</th>
<th>Numb er of Subjects</th>
<th>QoL instruments used * Significant improvement vs comparator † No significant improvement vs comparator ‡ No significance data provided</th>
<th>Psoriasis severity scale used (Primary)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asahina 2010 64</td>
<td>3</td>
<td>Adalimumab vs Placebo</td>
<td>24</td>
<td>169</td>
<td>DLQI*, SF-36*</td>
<td>PASI</td>
</tr>
<tr>
<td>Genovese 2007 65</td>
<td>4</td>
<td>Adalimumab vs Placebo</td>
<td>12</td>
<td>100</td>
<td>DLQI*, HAQ-DI*, SF-36* (PCS ONLY), FACIT F†</td>
<td>PGA</td>
</tr>
<tr>
<td>Mease 2005 66</td>
<td>4</td>
<td>Adalimumab vs Placebo</td>
<td>24</td>
<td>313</td>
<td>DLQI*, HAQ-DI*, SF-36* (PCS ONLY)</td>
<td>PASI</td>
</tr>
<tr>
<td>Study</td>
<td>Comparison</td>
<td>Weeks</td>
<td>N</td>
<td>Outcomes</td>
<td>Measure</td>
<td></td>
</tr>
<tr>
<td>------------------</td>
<td>------------------------------------------------</td>
<td>-------</td>
<td>----</td>
<td>-----------------------------------------</td>
<td>---------------</td>
<td></td>
</tr>
<tr>
<td>Shikiar 2007</td>
<td>Adalimumab vs Placebo</td>
<td>12</td>
<td>148</td>
<td>DLQI*, EQ-5D*, SF-36* (except for PCS in 40 MG EOW ARM)</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revicki 2007</td>
<td>Adalimumab vs Placebo</td>
<td>16</td>
<td>1212</td>
<td>DLQI*, SF-36*</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Revicki 2008</td>
<td>Adalimumab vs MTX</td>
<td>16</td>
<td>271</td>
<td>DLQI*, EQ-5D*</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thaci 2010</td>
<td>Adalimumab + CAL/BD vs Adalimumab + Vehicle</td>
<td>16</td>
<td>730</td>
<td>DLQI†</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lui 2012</td>
<td>Alefacept vs nUVB</td>
<td>16</td>
<td>98</td>
<td>DLQI†</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Ellis 2003</td>
<td>Alefacept vs Placebo</td>
<td>12</td>
<td>205</td>
<td>DLQI⁰, SF-36⁰, DQOLS⁰</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Finlay 2003</td>
<td>Alefacept vs Placebo</td>
<td>12</td>
<td>507</td>
<td>DLQI†, DQOLS† (15 MG ARM ONLY), SF-36† (PCS ONLY)</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Yan 2011</td>
<td>Alefacept vs MTX</td>
<td>12</td>
<td>212</td>
<td>DLQI†, SF-36†</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Papp 2014</td>
<td>Briakinumab vs Placebo</td>
<td>12-40</td>
<td>2209</td>
<td>DLQI†, SF-36†</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Gordon 2014</td>
<td>Brodalumab vs Placebo</td>
<td>12</td>
<td>198</td>
<td>DLQI†, SF-36† (140 MG ARM ONLY, and MCS for 210 MG ARM)</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Gladman 2014</td>
<td>Certolizumab vs Placebo</td>
<td>24</td>
<td>409</td>
<td>DLQI†, SF-36†, PSAQOL†, HAQ-DI†</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Duration</td>
<td>Patients</td>
<td>Outcome Measures</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------</td>
<td>----------------------------------</td>
<td>----------</td>
<td>----------</td>
<td>------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reich 2012 92</td>
<td>Certolizumab vs Placebo</td>
<td>12</td>
<td>176</td>
<td>DLQI^0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dubertret 2006 38</td>
<td>Efalizumab vs Placebo</td>
<td>12</td>
<td>793</td>
<td>DLQI^−, SF-36^−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gordon 2003 3</td>
<td>Efalizumab vs Placebo</td>
<td>12</td>
<td>556</td>
<td>DLQI^−, PSA^−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cassano 2006 94</td>
<td>Etanercept (Dose-comparison)</td>
<td>12</td>
<td>108</td>
<td>DLQI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dauden 2009 95</td>
<td>Etanercept (Continuous vs Intermittent)</td>
<td>54</td>
<td>720</td>
<td>DLQI^0, EQ-5D^0, SF-36^0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gelfand 2008 17</td>
<td>Etanercept (Continuous vs Intermittent)</td>
<td>24</td>
<td>2546</td>
<td>DLQI^0, EQ-5D^0, HAQ-DI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gniadecki 2012 99</td>
<td>Etanercept (Dose-comparison)</td>
<td>12</td>
<td>752</td>
<td>DLQI^−, EQ-5D^†, HAQ-DI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lynde 2012 101</td>
<td>Etanercept vs Etanercept + nUVB</td>
<td>12</td>
<td>75</td>
<td>DLQI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ortonne 2013 102</td>
<td>Etanercept (Dose-comparison)</td>
<td>24</td>
<td>72</td>
<td>DLQI^0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thaci 2014 5</td>
<td>Etanercept (Dose-comparison)</td>
<td>12</td>
<td>273</td>
<td>DLQI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zachariae 2008 104</td>
<td>Etanercept + MTX (Tapered vs Continued)</td>
<td>24</td>
<td>59</td>
<td>DLQI^−, EQ-5D^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Krueger 2005 105</td>
<td>Etanercept vs Placebo</td>
<td>12</td>
<td>583</td>
<td>DLQI^−, SF-36^−</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Feldman 2005 107</td>
<td>Etanercept vs Placebo</td>
<td>12</td>
<td>652</td>
<td>DLQI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gottlieb 2003 109</td>
<td>Etanercept vs Placebo</td>
<td>24</td>
<td>112</td>
<td>DLQI^†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Study Source</td>
<td>Trial Duration</td>
<td>Treatment Comparison</td>
<td>Sample Size</td>
<td>Follow-up</td>
<td>Outcome Measures</td>
<td></td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------</td>
<td>----------------------</td>
<td>-------------</td>
<td>-----------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Reich 2009 110 (Van de Kerkhof 2008 111)</td>
<td>5</td>
<td>Etanercept vs Placebo</td>
<td>12</td>
<td>142</td>
<td>DLQI*, SF-36*</td>
<td></td>
</tr>
<tr>
<td>Tyring 2007 112 (Tyring 2006 113)</td>
<td>5</td>
<td>Etanercept vs Placebo</td>
<td>12</td>
<td>618</td>
<td>DLQI*</td>
<td></td>
</tr>
<tr>
<td>Reich 2013 35, extension of trial Barker 2011 114</td>
<td>2</td>
<td>Infliximab (Continuous vs Intermittent)</td>
<td>100</td>
<td>441</td>
<td>DLQI0, SF-360</td>
<td></td>
</tr>
<tr>
<td>Yang 2012 115</td>
<td>2</td>
<td>Infliximab vs Placebo</td>
<td>10</td>
<td>129</td>
<td>DLQI*</td>
<td></td>
</tr>
<tr>
<td>Barker 2011 114</td>
<td>3</td>
<td>Infliximab vs MTX</td>
<td>16</td>
<td>868</td>
<td>DLQI*, SF-36* (PCS ONLY), EQ-5D*</td>
<td></td>
</tr>
<tr>
<td>Feldman 2008 116 (Menter 2007 117)</td>
<td>4</td>
<td>Infliximab vs Placebo</td>
<td>10</td>
<td>1430</td>
<td>DLQI*, SF-36*</td>
<td></td>
</tr>
<tr>
<td>Torii 2010 118</td>
<td>4</td>
<td>Infliximab vs Placebo</td>
<td>14</td>
<td>54</td>
<td>DLQI*</td>
<td></td>
</tr>
<tr>
<td>Bissonnette 2011 119</td>
<td>5</td>
<td>Infliximab vs Placebo</td>
<td>14</td>
<td>24</td>
<td>DLQI†</td>
<td></td>
</tr>
<tr>
<td>Feldman 2005 120 (Gottlieb 2004 121)</td>
<td>5</td>
<td>Infliximab vs Placebo</td>
<td>10</td>
<td>249</td>
<td>DLQI*</td>
<td></td>
</tr>
<tr>
<td>Reich 2006 122 (Reich 2005 123)</td>
<td>5</td>
<td>Infliximab vs Placebo</td>
<td>24</td>
<td>378</td>
<td>DLQI*, SF-36*</td>
<td></td>
</tr>
<tr>
<td>Krupashankar 2014 124</td>
<td>4</td>
<td>Itolizumab (Loading dose vs. Non-loading dose)</td>
<td>12</td>
<td>225</td>
<td>DLQI0, SF-360</td>
<td></td>
</tr>
<tr>
<td>Leonardi 2012 125</td>
<td>5</td>
<td>Ixekizumab vs Placebo</td>
<td>8</td>
<td>142</td>
<td>DLQI*</td>
<td></td>
</tr>
<tr>
<td>Langley 2014 126</td>
<td>4</td>
<td>Secukinumab vs Etanercept vs Placebo</td>
<td>12</td>
<td>2044</td>
<td>DLQI* (VS PLACEBO ONLY)</td>
<td></td>
</tr>
</tbody>
</table>

Columns: Study Source, Trial Duration, Treatment Comparison, Sample Size, Follow-up, Outcome Measures
<table>
<thead>
<tr>
<th>Study Year</th>
<th>Treatment</th>
<th>Patients</th>
<th>Duration</th>
<th>Outcomes</th>
<th>Endpoint</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mamolo 2014  127</td>
<td>Tofacitinib vs Placebo</td>
<td>12</td>
<td>197</td>
<td>DLQI*, SF-36*</td>
<td>PASI</td>
</tr>
<tr>
<td>Paul 2014  128 (Reich 2014  129)</td>
<td>Ustekinumab + MTX (Gradual vs. Immediate withdrawal)</td>
<td>16</td>
<td>489</td>
<td>DLQI0, EQ-5D0, VAS0</td>
<td>PASI</td>
</tr>
<tr>
<td>Nakagawa 2012  130 (Igarashi 2012  131)</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>158</td>
<td>DLQI*, SF-36* (PCS ONLY), PDI*</td>
<td>PASI</td>
</tr>
<tr>
<td>Kimball 2012  132 (Leonardi 2008 133, Lebwohl 2010 134, Kimball 2013 135)</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>766</td>
<td>DLQI*, SF-360</td>
<td>PASI</td>
</tr>
<tr>
<td>Zhu 2013  136</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>322</td>
<td>DLQI*</td>
<td>PASI</td>
</tr>
<tr>
<td>Langley 2010  137 (Papp 2008 138,139)</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>1230</td>
<td>DLQI*</td>
<td>PASI</td>
</tr>
<tr>
<td>McInnes 2013  140</td>
<td>Ustekinumab vs Placebo</td>
<td>24</td>
<td>615</td>
<td>DLQI*, HAQ-DI*, SF-36* (EXCEPT MCS IN 45 MG ARM)</td>
<td>PASI</td>
</tr>
<tr>
<td>Kavanaugh 2010 141 (Gottlieb 2009 142)</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>146</td>
<td>DLQI*, HAQ-DI*</td>
<td>PASI</td>
</tr>
<tr>
<td>Tsai 2012  143 (Tsai 2011 144)</td>
<td>Ustekinumab vs Placebo</td>
<td>12</td>
<td>121</td>
<td>DLQI*</td>
<td>PASI</td>
</tr>
<tr>
<td>Strand 2013  145 (Papp 2012 146)</td>
<td>Apremilast vs Placebo</td>
<td>16</td>
<td>352</td>
<td>DLQI* (EXCEPT 10 MG ARM), SF 36* (MCS ONLY)</td>
<td>PASI</td>
</tr>
</tbody>
</table>

**SYSTEMICS**
<table>
<thead>
<tr>
<th>Study</th>
<th>Year</th>
<th>Intervention</th>
<th>Participants</th>
<th>Outcome Measures</th>
<th>Conclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Möller 2010</td>
<td>2010</td>
<td>Chondroitin Sulphate vs Placebo</td>
<td>12</td>
<td>116</td>
<td>DLQI*, SF-36*</td>
</tr>
<tr>
<td>Beissert 2009</td>
<td>2009</td>
<td>Ciclosporin vs Mycophenolate Mofetil</td>
<td>12</td>
<td>54</td>
<td>PDI†</td>
</tr>
<tr>
<td>Thaci 2002</td>
<td>2002</td>
<td>Ciclosporin (Body-weight dependent dose vs Independent dose)</td>
<td>12</td>
<td>212</td>
<td>PDI⁰</td>
</tr>
<tr>
<td>Roberti 2014</td>
<td>2014</td>
<td>Cytokines (low dose)</td>
<td>12</td>
<td>41</td>
<td>DLQI*</td>
</tr>
<tr>
<td>Bagel 1998</td>
<td>1998</td>
<td>DAB389IL02 vs Placebo</td>
<td>2</td>
<td>70</td>
<td>DLQI⁰</td>
</tr>
<tr>
<td>Greenberger 2012</td>
<td>2012</td>
<td>Dunaliella bardawil (9-cis b-carotene) vs Placebo</td>
<td>12</td>
<td>44</td>
<td>DLQI*</td>
</tr>
<tr>
<td>Salim 2006</td>
<td>2006</td>
<td>MTX + Folic acid vs MTX</td>
<td>5</td>
<td>22</td>
<td>DLQI†</td>
</tr>
<tr>
<td>Kaltwasser 2004</td>
<td>2004</td>
<td>Leflunomide vs Placebo</td>
<td>5</td>
<td>190</td>
<td>DLQI*, HAQ*</td>
</tr>
<tr>
<td>Faurschou 2014</td>
<td>2014</td>
<td>Liraglutide vs Placebo</td>
<td>4</td>
<td>20</td>
<td>DLQI†</td>
</tr>
<tr>
<td>Flyström 2008</td>
<td>2008</td>
<td>MTX vs Ciclosporin</td>
<td>3</td>
<td>84</td>
<td>DLQI*, SF-36* (PCS ONLY)</td>
</tr>
<tr>
<td>Asawanonda 2006</td>
<td>2006</td>
<td>MTX + nUVB vs MTX + Placebo</td>
<td>4</td>
<td>24</td>
<td>DLQI†</td>
</tr>
<tr>
<td>Ho 2010</td>
<td>2010</td>
<td>Traditional Chinese Medicine vs MTX</td>
<td>2</td>
<td>61</td>
<td>PDI* (FOR MTX VS PLACEBO)</td>
</tr>
<tr>
<td>Gupta 2008</td>
<td>2008</td>
<td>Voclosporin vs Placebo</td>
<td>3</td>
<td>201</td>
<td>DLQI⁰, PDΙ⁰</td>
</tr>
<tr>
<td>Kunynetz 2011</td>
<td>2011</td>
<td>Voclosporin vs Placebo</td>
<td>5</td>
<td>451</td>
<td>DLQI* (FOR 0.3 AND 0.4 MG ARMS), PDI* (FOR 0.3 AND 0.4 MG ARMS)</td>
</tr>
<tr>
<td>Study Reference</td>
<td>n</td>
<td>Intervention</td>
<td>Comparator</td>
<td>Duration (weeks)</td>
<td>Outcomes (main)</td>
</tr>
<tr>
<td>-----------------</td>
<td>---</td>
<td>-------------</td>
<td>------------</td>
<td>-----------------</td>
<td>-----------------</td>
</tr>
<tr>
<td>Drouin 2008</td>
<td>5</td>
<td>XP-828L (Dermylex) vs Placebo</td>
<td>8</td>
<td>26</td>
<td>DLQI*, PASI</td>
</tr>
<tr>
<td>Koek 2009 (Koek 2006)</td>
<td>2</td>
<td>Home UVB (TL-01) vs Outpatient UVB (TL-01)</td>
<td>'46 irradiations'</td>
<td>196</td>
<td>PDI†, SF-36⁰, EQ-5D⁰</td>
</tr>
<tr>
<td>Gahalaut 2014</td>
<td>2</td>
<td>PUVAsol + Isotretinoin vs PUVAsol</td>
<td>12</td>
<td>40</td>
<td>DLQI*, PASI</td>
</tr>
<tr>
<td>Klein 2011</td>
<td>2</td>
<td>Synchronous balneophototherapy vs nUVB monotherapy</td>
<td>'35 sessions'</td>
<td>367</td>
<td>PDI†, SIP*, FLQA-d* (PHYSICAL COMPLAINTS AND GLOBAL HEALTH ONLY)</td>
</tr>
<tr>
<td>Choonhakarn 2010</td>
<td>4</td>
<td>Aloe Vera vs Triamcinolone Acetonide</td>
<td>8</td>
<td>75</td>
<td>DLQI†, PASI</td>
</tr>
<tr>
<td>Ortonne 2014</td>
<td>5</td>
<td>Betamethasone valerate dressing vs CAL/BD ointment</td>
<td>4</td>
<td>324</td>
<td>DLQI†, TSS-4</td>
</tr>
<tr>
<td>Wall 1998</td>
<td>1</td>
<td>CAL vs Dithranol</td>
<td>12</td>
<td>306</td>
<td>PDI†, SIP†</td>
</tr>
<tr>
<td>Ortonne 2009 (Kragballe 2009)</td>
<td>2</td>
<td>CAL/BD scalp formulation vs CAL scalp solution</td>
<td>8</td>
<td>312</td>
<td>SF-36†, Skindex-16, TSS</td>
</tr>
<tr>
<td>Study (Year)</td>
<td>Treatments</td>
<td>Weeks</td>
<td>Study Population</td>
<td>Primary Outcomes</td>
<td>Additional Outcomes</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>-------</td>
<td>------------------</td>
<td>------------------</td>
<td>---------------------</td>
</tr>
<tr>
<td>Saraceno 2007 167</td>
<td>CAL/BD vs CAL</td>
<td>4</td>
<td>150</td>
<td>Skindex-29*</td>
<td>PASI</td>
</tr>
<tr>
<td>Zheng 2011 168</td>
<td>CAL/BD vs CAL</td>
<td>4</td>
<td>320</td>
<td>DLQI*</td>
<td>VAS</td>
</tr>
<tr>
<td>De Korte 2008 &amp; Van De Kerkhof 2006 169</td>
<td>CAL vs Dithranol</td>
<td>12</td>
<td>106</td>
<td>Skindex-29†, SF-36†</td>
<td>Modified PASI</td>
</tr>
<tr>
<td>Menter 2013 170</td>
<td>CAL/BD vs BD vs CAL vs Vehicle</td>
<td>8</td>
<td>1152</td>
<td>DLQI* (EXCEPT VS CAL GROUP)</td>
<td>PASI</td>
</tr>
<tr>
<td>Van De Kerkhof 2004 171</td>
<td>CAL/BD vs CAL vs Placebo</td>
<td>4</td>
<td>828</td>
<td>EQ-5D*, PDI†</td>
<td>PASI</td>
</tr>
<tr>
<td>Woo 2003 172</td>
<td>CAL + nUVB vs CAL vs Vehicle</td>
<td>20 sessions</td>
<td>50</td>
<td>PDI†</td>
<td>PASI</td>
</tr>
<tr>
<td>Hutchinson 2000 173</td>
<td>Calcitriol vs Dithranol</td>
<td>8</td>
<td>114</td>
<td>PDI‘</td>
<td>PASI</td>
</tr>
<tr>
<td>Bergstrom 2003 174</td>
<td>Clobetasol (Foam vs Cream/Solution)</td>
<td>2</td>
<td>32</td>
<td>DLQI†, EQ-5D*</td>
<td>PASI</td>
</tr>
<tr>
<td>Menter 2009 4</td>
<td>Clobetasol propionate vs Calcipotriene + Betamethasone dipropionate</td>
<td>4</td>
<td>93</td>
<td>PQOLS†</td>
<td>ODS</td>
</tr>
<tr>
<td>Mraz 2008 175</td>
<td>Clobetasol propionate (Spray vs Foam)</td>
<td>2-4</td>
<td>77</td>
<td>DLQI†</td>
<td>IGS</td>
</tr>
<tr>
<td>Sofen 2011 176</td>
<td>Clobetasol propionate spray vs Vehicle</td>
<td>4</td>
<td>81</td>
<td>Scalpdex‘</td>
<td>GSS</td>
</tr>
<tr>
<td>Prins 2005 177</td>
<td>Dithranol (Short contact) + nUVB vs Dithranol (Inpatient)</td>
<td>8-12</td>
<td>238</td>
<td>SIP‘, PDI‘</td>
<td>PASI</td>
</tr>
<tr>
<td>Study</td>
<td>N</td>
<td>Intervention</td>
<td>DLQI Score</td>
<td>PASI</td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----</td>
<td>-------------------------------------------------------------------------------</td>
<td>------------</td>
<td>------</td>
<td></td>
</tr>
<tr>
<td>Alora-Palli 2010</td>
<td>2</td>
<td>Liquor Carbonis Distillate (LCD) Solution vs Calcipotriene cream</td>
<td>12</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Bernstein 2006</td>
<td>2</td>
<td>M. Aquifolium vs Placebo</td>
<td>12</td>
<td>200</td>
<td></td>
</tr>
<tr>
<td>Tiplica 2009</td>
<td>3</td>
<td>Mometasone furoate 0.1% + Salicylic acid 5% vs Mometasone furoate 0.1%</td>
<td>1</td>
<td>359</td>
<td></td>
</tr>
<tr>
<td>Galvez 2012</td>
<td>3</td>
<td>Sulphurous Mineral Waters Spray vs Distilled Water Spray</td>
<td>2</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>Lu 2012</td>
<td>2</td>
<td>Auricular therapy + Yinxieling formula vs Yinxieling formula</td>
<td>8</td>
<td>84</td>
<td></td>
</tr>
<tr>
<td>Schmitt 2014</td>
<td>3</td>
<td>Interdisciplinary dermatological and psychiatric care for psoriasis vs Dermatological care for psoriasis</td>
<td>24</td>
<td>47</td>
<td></td>
</tr>
<tr>
<td>Ersser 2012</td>
<td>2</td>
<td>Educational nursing intervention vs No education intervention</td>
<td>6</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>Bostoen 2012</td>
<td>4</td>
<td>Educational programme vs No educational intervention</td>
<td>12</td>
<td>29</td>
<td></td>
</tr>
<tr>
<td>Vedhara 2007</td>
<td>2</td>
<td>Emotional disclosure vs Standard control writing intervention</td>
<td>0.5</td>
<td>59</td>
<td></td>
</tr>
<tr>
<td>Guida 2014</td>
<td>2</td>
<td>Patients on immunosuppressives: Energy-restricted diet vs Usual diet</td>
<td>24</td>
<td>44</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Treatment</td>
<td>Patients</td>
<td>Outcomes</td>
<td>Results</td>
<td>Comments</td>
</tr>
<tr>
<td>------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>----------</td>
<td>-------------------</td>
<td>---------</td>
<td>----------</td>
</tr>
<tr>
<td>Jensen 2013 [187]</td>
<td>Low energy diet vs Standard routine dietary guidance</td>
<td>16</td>
<td>60</td>
<td>DLQI*</td>
<td>PASI</td>
</tr>
<tr>
<td>Fordham 2014 [188]</td>
<td>MCBT vs Usual treatment</td>
<td>8</td>
<td>29</td>
<td>DLQI†</td>
<td>SAPASI</td>
</tr>
<tr>
<td>Chambers 2012 [189]</td>
<td>Online Healthcare Delivery vs In-Office Care</td>
<td>16</td>
<td>64</td>
<td>DLQI0,  EQ-5D0</td>
<td>PASI</td>
</tr>
<tr>
<td>Tabolli 2012 [190]</td>
<td>Writing exercise (Pennebaker) vs Educational intervention</td>
<td>0.5</td>
<td>202</td>
<td>Skindex-29†, SF-36†, GHQ†</td>
<td>PASI</td>
</tr>
</tbody>
</table>

MTX – Methotrexate  
nUVB – Narrowband UVB  
MCBT - Mindfulness-based cognitive therapy  
CALC – Calipotriol  
BD – Betamethasone dipropionate

* Indicates significant improvement versus comparator(s)  
† Indicates no significant improvement versus comparator(s)  
0 Indicates no significance data was provided
Records identified through database searching
- Medline (n=638)
- Medline in Progress (n=54)
- EMBASE (n=611)
- Scopus (n=938)
- Web of Science (n=1185)
- Cochrane CENTRAL (n=167) (n=3593)

Additional records identified through other sources
- Trial registries (n=48)
- Hand searching (n=5) (n=53)

First screening (after duplicates removed) (n=2016)

Records excluded on basis of title and abstract (n=1687)

Full-text articles assessed for eligibility (n=329)

Full-text articles excluded with reasons (n=230)

Articles included in the systematic review (n=99)

Reasons for exclusion
- No quality of life data (113)
- Language other than English (4)
- Not a randomised controlled trial (20)
- Psoriatic Arthritis trials without skin-relevant QoL data (14)
- Salami publication of primary study (46)
- No full articles available after contacting authors; these include conference abstracts, letters to editor, meeting posters, and trial protocols (15)
- QoL data unable to be extracted (14)
- Trials including subjects under the age of 18 (4)

Figure 1. Flow diagram of article selection
Figure 2. Number of randomised controlled trials of each intervention that measured HRQoL.
Figure 3(a)

Figure 3(b)

Figure 3. Correlation of (a) absolute change in DLQI scores with absolute change in PASI scores \((R^2 = 0.494)\) (b) percentage improvement in DLQI scores with percentage improvement in PASI scores \((R^2 = 0.641)\)
Figure 4. Increasing use of QoL instruments in included psoriasis studies since 1998 (n=100)
Example search strategy

**Medline OVID search strategy**

1. psoriasis.mp.orexpPsoriasis/
2. psoria*.mp.
3. erythrodermicpsoriasis.mp.
4. guttatepsoriasis.mp.
5. pustularpsoriasis.mp.
6. palmoplanterpsoriasis.mp.
7. psoriasisvulgaris.mp.
8. plaquepsoriasis.mp.
9. localisedpustularpsoriasis.mp.
10. localizedpustularpsoriasis.mp.
11. inversepsoriasis.mp.
12. scalppsoriasis.mp.
13. nailpsoriasis.mp.
14. inflammatorypsoriasis.mp.
15. or/1-14
16. intervention*.mp.
17. treatment*.mp.
18. topical.mp.
19. systemic.mp.
20. immunosuppressivedrug.mp.
21. ImmunosuppressiveAgents/
22. NonprescriptionDrugs/
23. over-the-counter.mp.
24. otc.mp.
25. expTars/
27. expSteroids/
28. expRetinoids/
29. retinoid*.tw.
30. steroid*.tw.
31. expemollientagent/
32. emollient*.tw.
33. expTacrolimus/
34. tacrolimus.tw.
35. topicalimmunemodulator*.tw.
36. (topicaladj3therap*).tw.
37. (topicaladj3treatment*).tw.
38. (topicaladj3agent*).tw.
39. vitaminDanalogues.mp.
40. calcipotriol.mp.
41. dovonex.tw.
42. dovobet.tw.
43. xamiol.tw.
44. calcipotriene.mp.
45. taclonex.tw.
46. Calcitriol/orcalcitriol.mp.
47. silkis.tw.
48. tacalcitol.mp.
49. curatoderm.tw.
50. vitaminD.tw.
51. tars.mp.orTars/
52. (calamineandcoaltarointment).mp.
53. coaltar.mp.
54. calamine.mp.
55. (coaltarandsalicylicacidointment).mp.
56. coaltarpaste.mp.
57. (zincandcoaltarpaste).mp.
58. zincoxide.mp.
59. alphosyl.mp.
60. crudecoaltar.mp.
61. dithranol.mp.
62. anthralin.mp.orAnthralin/
63. dithrocream.tw.
64. micanol.tw.
65. psorin.tw.
66. zithranol.tw.
67. topicalretinoids.mp.
68. tazarotene.mp.
69. zorac.tw.
70. tazorac.tw.
71. corticosteroid.mp.
72. hydrocortisone.mp.orHydrocortisone/
73. dioderm.tw.
74. mildison.tw.
75. alphaderm.tw.
76. calmuridHC.tw.
77. eurax-hydrocortisone.tw.
78. canestenHC.tw.
79. daktacort.tw.
80. fucidinH.tw.
81. nystaform-HC.tw.
82. timodine.tw.
83. hydrocortisonebutyrat.mp.
84. locoid.tw.
85. locoidcrelo.tw.
86. alclometasonedipropionate.mp.
87. modrasone.tw.
88. betamethasoneesters.mp.
89. betamethasonevalerate.tw.
90. betacap.tw.
91. betesil.tw.
92. betnovate.tw.
93. betnovate-rd.tw.
94. bettamousse.tw.
95. diprosone.tw.
96. diprosalic.tw.
97. betnovate-c.tw.
98. betnovate-n.tw.
99. fucibet.tw.
100. lotriderm.tw.
101. clobetasolpropionate.mp.
102. clarelux.tw.
103. dermovate.tw.
104. etrivex.tw.
105. dermovate-nn.tw.
106. clobetasonbutyrate.mp.
107. eumovate.tw.
108. diflucortolonevalerate.mp.
109. nerisone.tw.
110. nerisoneforte.tw.
111. fludroxy cortide.mp.
112. flurandrenolonelone.tw.
113. haelan.tw.
114. fluocinoloneacetonide.mp.orFluocinoloneAcetonide/
115. synalar1in4dilution.tw.
116. synalar1in10dilution.tw.
117. synalarc.tw.
118. synalarn.tw.
119. fluocinonide.mp.orFluocinonide/
120. metosyn.tw.
121. fluocortolone.mp.orFluocortolone/
122. ultralanumplain.tw.
123. fluticasonepropionate.mp.
124. cutivate.tw.
125. mometasonefuroate.mp.
126. elocon.tw.
127. triamcinoloneacetonide.mp.orTriamcinoloneAcetonide/
128. aureocort.tw.
129.Keratolytic Agents/or Keratolytic.mp.
130.salicylic acid.mp.or Salicylic Acid/
131.zinc.mp. and salicylic acid paste.tw.
132.Sulfur/or sulphur.mp.
133.exp Ultraviolet Rays/
134.exp Ultraviolet Therapy/
135.ultraviolet*.tw.
136.(uv or UVB or UVA).tw.
137.phototherapy.mp.or Phototherapy/
138.ultravioletb.mp.
139.UVB.mp.
140.narrow band UVB.mp.
141.narrow-band UVB.mp.
142.narrowband UVB therapy.mp.
143.broad band light therapy.mp.
144.ultraviolet light.mp.
145.UV light.mp.
146.natural light.mp.
147.combination light therapy.mp.
148.photochemotherapy.mp.or Photochemotherapy/
149.psoralen.mp.
150.PUVA.mp.
151.or al retinoids.mp.
152.acitretin.mp.or Acitretin/
153.neotigason.tw.
154.cyclosporin.mp.or Cyclosporine/
155.ciclosporin.mp.
156.deximune.tw.
157.neoral.tw.
158.sandimmune.tw.
159.hydroxycarbamide.mp.
160.hydrea.tw.
161.hydroxyurea.mp.or Hydroxyurea/
162.methotrexate.mp.orMethotrexate/
163.metoject.tw.
164.cytokinemodulators.mp.
165.etanercept.mp.
166.enbrel.tw.
167.adalimumab.mp.
168.humira.tw.
169.infliximab.mp.
170.remicade.tw.
171.ustekinumab.mp.
172.stelara.tw.
173.efalizumab.mp.
174.raptiva.tw.
175.biologic*.mp.
176.Psychotherapy/
177.(psycho*adj3therap*).tw.
178.psychotherap*.tw.
179.expCognitiveTherapy/
180.(cognit*adj3therap*).tw.
181.((behaviourorbehavior)adj3therap*).tw.
182.psychoeeducation.tw.
183.CBT.tw.
184.expPeerGroup/
185.expSelf-HelpGroups/
186.(peeradj3group*).tw.
187.((supportorself-helporselfhelp)adj3group*).tw.
188.alternativetherapy.mp.
189.homeopathy.mp.orHomeopathy/
190.Relaxation/orrelaxation.mp.
191.oreganooil.mp.
192.traditionaltreatment*.mp.
193.oatextracts.mp.
194.coldwaterfishoils.mp.
195.eveningprimroseoil.mp.
196.teatreeoil.mp."TeaTreeOil"/
197.aloe vera.mp.Aloe/
198.taichi.mp.
199.yoga.mp.Yoga/
200.laser.mp.
201.herbalmedication.mp.
202.petroleumjelly.mp.
203.massage*.mp.
204.sharkcartilageextract.mp.
205.meditation.mp.Meditation/
206.complementarytherapy.mp.ComplementaryTherapies/
207.hypnotherapy.mp.
208.milkthistle.mp.MilkThistle/
209.expMotorActivity/
210.(physicaladj3activit$).tw.
211.expExercise/
212.expExerciseTherapy/
213.exercis$.tw.
214.expLifeStyle/
215.lifestyle$.tw.
216.(lifeadj3style$).tw.
217.expHealthBehavior/
218.(healthadj3(behavior$orbehaviour$)).tw.
219.expDiet/
220.expDietarySupplements/
221.diet$.tw.
222.nutrition$.tw.
223.expObesity/
224.expBodyWeight/
225.obes$.tw.
226.weight$.tw.
227.expSmoking/
228.(smokingorsmoker*).tw.
229.expAlcohol-RelatedDisorders/
230.expAlcoholicBeverages/
231.alcohol*.tw.
232.drinking.tw.
233.expEmployment/
234.expOccupations/
235.(employment*oroccupation*orwork).tw.
236.goeckermantherapy.mp.
237.excimertherapy.mp.
238.scalelifters.mp.
239.non-biologicalmedications.mp.
240.FishOils/orfishoil*.mp.
241.vitamins.mp.orVitamins/
242.vitaminE.mp.orVitaminE/
244.mineral*.mp.
245.selenium.mp.orSelenium/
246.Antimetabolites/orantimetabolite*.mp.
247.thioguanine.mp.orThioguanine/
248.tioguanine.mp.
249.misccellaneous.mp.
250.immunomodulatoragents.mp.
251.immunomodulatordrugs.mp.
252.calcineurininhibitors.mp.
253.anti-itch.mp.
254.e45cream.mp.
255.fumaricacidesters.mp.
256.fumaricacidesters.mp.
257.FAE.mp.
258.sorbelene.mp.
259.anti-fungal.mp.
260.skinbiopsy.mp.
261.alefacept.mp.
262.amevive.tw.
263.or/16-262
264.QOL.mp.
265.qualityoflife.mp.or"QualityofLife"/
266.healthrelatedqualityoflife.mp.
267.HRQOL.mp.
268.EQ5D.mp.
269.nationalpsoriasisfoundation.mp.
270.skindex.mp.
271.DLQI.mp.
272.dermatologylifequalityindex.mp.
273.burdenofskindisease.mp.
274.patientreportedoutcomemeasure.mp.
275.qualityoflifeimpairment.mp.
276.outcomemeasurement.mp.
277."OutcomeAssessment(HealthCare)"/oroutcomeassessment.mp.
278.QOLtools.mp.
279.patientreportedoutcome.mp.
280.PRO.mp.
281.NHP.mp.
282.WHO-QOL.mp.
283.psoriasisdisabilityindex.mp.
284.PDI.mp.
285.salfordpsoriasisindex.mp.
286.SPI.mp.
287.FDLQI.mp.
288.PFI.mp.
289.skindex-16.mp.
290.skindex-29.mp.
291.skindex-teen.mp.
292.childrensdermatologylifequalityindex.mp.
293.CDLQI.mp.
294. familydermatologylifequalityindex.mp.
295. psoriasis-specificmeasureofqualityoflife.mp.
296. PSORIQoL.mp.
297. USPSORIQoL.mp.
298. skindex-17.mp.
299. DQOLS.mp.
300. dermatologyqualityoflifescales.mp.
301. shortform-36.mp.
302. KMPI.mp.
303. PDI.mp.
304. nationalpsoriasisfoundationpsoriasisscore.mp.
305. NPF-PS.mp.
306. physicianstaticglobalassessment.mp.
307. PSGA.mp.
308. overalllesionassessment.mp.
309. OLA.mp.
310. physiciandynamicglobalassessment.mp.
311. physiciandynamicglobalassessment.mp.
312. PDGA.mp.
313. latticesystemglobalpsoriasisscore.mp.
314. LS-GPS.mp.
315. PsAQoL.mp.
316. dermatologyindexofdiseaseseverity.mp.
317. DIDS.mp.
318. psoriasislifestressinventory.mp.
319. PLSI.mp.
320. WHOQOL-26.mp.
321. WHOQOL-100.mp.
322. patientgeneralindex.mp.
323. PGI.mp.
324. DIELH.mp.
325. VQ-dermato.mp.
326. impactofchronicskindiseaseondailylife.mp.
327.ISDL.mp.
328.freiberglifequalityassessment.mp.
329.FLQA.mp.
330.SF-29.mp.
331.valueoflife/
332.qualityadjustedlifeyear/
333.qualityadjustedlife.tw.
334.(qaly$orqald$orqale$orqtime$).tw.
335.disabilityadjustedlife.tw.
336.daly$.tw.
337.healthstatusindicators/
338.(sf36orsf36orshortform36orsfthirtysixorsfthirtysixorshortformthirtysixorshortformthirtysixorshortformthirtysix).tw.
339.(sf6orsf6orshortform6orsfsixorsfsixorshortformsixorshortformsix).tw.
341.(sf16orsf16orshortform16orsfsixteenorsfsixteenorshortformsixteen).tw.
342.(sf20orsf20orshortform20orsftwentyorsftwentyorshortformtwentyorshortformtwenty).tw.
343.(euroqoloreuroqoloreq5doreq5d).tw.
344.(hqlorhqolorhqolorhqolorqol).tw.
345.(hyeorhyes).tw.
346.health$year$equivalent$.tw.
347.healthutilit$.tw.
348.(huiorhui1orhui2orhui3).tw.
349.disutili$.tw.
350.rosser.tw.
351.qualityofwellbeing.tw.
352.qwb.tw.
353.willingnesstopay.tw.
354.standardgamble$.tw.
388.historicalarticle/
389.or/386-388
390.385not389
391.15and263and358and390